http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
PharmaTher Enters Into Process Development Agreement With LTS LOHMANN for Ketamine Microneedle Patch
View Older Stories
-
PharmaTher Announces Positive Research Results for LSD Microneedle Patch
-
PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio
-
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus
-
PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch
-
PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch
-
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of Psilocybin Microneedle Patch
-
PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psychedelics
-
PharmaTher Provides Business Update and Releases Financial Results for the First Quarter of Fiscal 2022
-
World Leading Drug Delivery Researcher Professor Ryan Donnelly Joins PharmaTher as Scientific and Technical Advisor
-
PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products
-
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome
-
PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease
-
PharmaTher Retains Former FDA Psychiatry Division Director Dr. Thomas Laughren as Regulatory Affairs Advisor
-
PharmaTher Announces Closing of CAD$10 Million Private Placement with Institutional Investors
-
PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund
-
PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022
-
PharmaTher to Present at H.C. Wainwright 23rd Annual Global Investment Conference
-
PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021
-
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis
-
PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation
-
PharmaTher To Participate in Grizzle Psychedelics Con
-
PharmaTher To Present At The H.C. Wainwright Psychedelics In Psychiatry And Beyond Virtual Conference
-
PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression
-
PharmaTher Provides Research and Development Update and Milestones for 2021
-
PharmaTher and TSRL Enter into Co-Development Agreement For Microneedle Patch Delivery Technology for Psychedelics and Antivirals
-
PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation for Pain Disorders and to Discover Novel Psychedelic Formulations
-
PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease
-
Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher’s Ketamine Programs
-
PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease
-
PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI™
-
PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial Evaluating Ketamine in the Treatment of Parkinson’s Disease
-
PharmaTher Provides Update on Psychedelic Product Programs
-
Newscope Announces Name Change to PharmaTher Holdings Ltd.
-
Newscope Announces Name Change
-
Newscope Capital Provides Dial-In Information for Special Meeting
-
PharmaTher Advancing Research for Novel Microneedle Delivery of Ketamine
-
World Leading Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific and Clinical Advisor
-
PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig’s Disease
-
Newscope Announces DTC Eligibility of Its Common Shares in the United States
-
PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery of Psychedelic Pharmaceuticals
-
PharmaTher Announces Sale of Psilocybin Program
-
PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA for the Clinical Development of Ketamine in the Treatment of Parkinson’s Disease
-
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine
-
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders
-
PharmaTher Approved to Trade on the OTCQB Venture Market
-
PharmaTher Announces Application for OTCQB Listing
-
PharmaTher Signs LOI to Sell Psilocybin Program to Revive Therapeutics
-
Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program
-
PharmaTher Files U.S. Patent for Novel Combinations of Psilocybin and FDA Approved Drugs to Treat Neurological Disorders
-
PharmaTher Granted Pre-IND Meeting with the FDA for Ketamine in Parkinson’s Disease
